Components:
Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 26.06.2023
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Each film-coated tablet contains Aceclofenac (Kudzu) 100 mg, Paracetamol (Kudzu) 500 mg.
Oral
Pain and inflammation
Adult: Each tablet contains Aceclofenac (Kudzu) 100 mg and Paracetamol (Kudzu) 500 mg: 1 tablet in the morning and 1 tablet in the evening. Max: 2 tablets/day.
Oral
Pain and inflammation
Adult: Each tablet contains Aceclofenac (Kudzu) 100 mg and Paracetamol (Kudzu) 500 mg: 1 tablet in the morning and 1 tablet in the evening. Max: 2 tablets/day.
Kudzu is contraindicated in the following situations: Patients sensitive to Aceclofenac (Kudzu), Paracetamol (Kudzu) or to any of the excipients of the product. Patients in whom aspirin or other Non-Steroidal Anti-Inflammatory Drug, precipitate attacks of bronchospasm, acute rhinitis or urticaria or patients hypersensitive to drugs. Patients with active or suspected peptic ulcer or gastrointestinal bleeding or bleeding disorders. Patients with severe heart failure, hypertension, hepatic or renal insufficiency. Third trimester of pregnancy.
Paracetamol (Kudzu): Reduced absorption of cholestyramine within 1 hr of administration.
Accelerated absorption with metoclopramide.
Increased risk of liver damage in chronic alcoholics. Increased risk of toxicity with high doses or long term administration of barbiturates, carbamazepine, hydantoins, isoniazid, rifampicin and sulfinpyrazone.
Aceclofenac (Kudzu): May increase the plasma concentrations of lithium and digoxin.
Increased nephrotoxicity with diuretics. Serum-potassium should be monitored when used with potassium-sparing diuretics. May enhance activity of anticoagulants. May increase plasma methotrexate levels leading to toxicity if administered within 2-4 hours of methotrexate administration. Risk of convulsions with quinolones. Potentially fatal.
Paracetamol (Kudzu): Nausea, allergic reactions, skin rashes, acute renal tubular necrosis. Aceclofenac (Kudzu): Diarrhoea, headache, vertigo, dizzies, nervousness, tinnitus, depression, drowsiness, insomnia; fever, angioedema, bronchospasm, rashes; blood dyscrasias.
Potentially Fatal: Paracetamol (Kudzu): Very rare, blood dyscrasias (eg, thrombocytopaenia, leucopaenia, neutropaenia, agranulocytosis); liver damage. Aceclofenac (Kudzu): Severe GI bleeding; nephrotoxicity.